# AnHorn Medicines Co. Ltd.: Phase 1 study completed, 32 enrolled (Chemotherapy-induced Peripheral Neuropathy (CIPN))

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | AnHorn Medicines Co. Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Safety, Tolerability, and PK of AH-008 Following Single Ascending Dose in Healthy Subjects |
| NCT ID | NCT07697560 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Chemotherapy-induced Peripheral Neuropathy (CIPN) |
| Intervention types | drug |
| Target enrollment | 32 |
| Site countries | United States |
| Posted | 2026-07-13 |
| Planned start | 2026-06-10 |
| Event | Completed |
| Event date | 2026-09-25 |
| Last update posted | 2026-10-29 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07697560). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.